● Recruiting

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Condition: Retinitis Pigmentosa · Sponsor: Zhongmou Therapeutics

PhaseEARLY_Phase 1

Planned participants12

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersNo

About this study

This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.

This description comes directly from the study's public registry record.

Talk to the study team

Windy Zhou · +86 18986214263 · zmt@zmtherapeutics.com

Yin Shen

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tongren Hospital of Capital Medical University

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06292650